Join

Compare · BDX vs SGHT

BDX vs SGHT

Side-by-side comparison of Becton Dickinson and Company (BDX) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $42.51B, about 175.6x SGHT ($242.1M).
  • Over the past year, BDX is down 11.5% and SGHT is up 46.1% - SGHT leads by 57.5 points.
  • BDX has been more active in the news (15 items in the past 4 weeks vs 8 for SGHT).
  • BDX has more recent analyst coverage (25 ratings vs 19 for SGHT).
PerformanceBDX-11.46%SGHT+46.05%
2025-05-02+0.00%2026-05-01
MetricBDXSGHT
Company
Becton Dickinson and Company
Sight Sciences Inc.
Price
$149.44+0.23%
$4.44+8.82%
Market cap
$42.51B
$242.1M
1M return
-4.40%
+21.15%
1Y return
-11.46%
+46.05%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
15
8
Recent ratings
25
19
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

SGHT

Sight Sciences Inc.

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Latest BDX

Latest SGHT